IPCOR announcement receives widespread media coverage

The announcement earlier this week that €1.75 million in funding will be dedicated by the Irish Cancer Society, in collaboration with Movember, to establish the first Irish Prostate Cancer Outcomes Research (IPCOR) has received widespread media coverage this week.

The aim of IPCOR is to effectively record and report on outcomes of prostate cancer treatment and care with a view to improving the lives of those living with and beyond prostate cancer. It aims to build on the National Cancer Registry data, by collecting data for all newly diagnosed prostate cancer cases in Ireland with the involvement of clinicians who treat men with prostate cancer.

It is seen as a ground-breaking new direction, with Irish Cancer Society Head of Research, Prof John Fitzpatrick, saying: “For reasons that are not clear, the incidence of prostate cancer here is quite high.

“The beauty of Ireland is that it is small enough to do a countrywide study where everybody treated for prostate cancer in the country will be part of this. This is the first time this has been done anywhere in the world for any cancer.”

The deadline for applications is September 6th. Eligible organisations to apply for the IPCOR grant include recognised Research Institutions and State Agencies in the Republic of Ireland.

There is more information on the announcement of IPCOR here.

Full guidelines of how organisations can apply here.

Click the following links to read media coverage of the IPCOR announcement.

• Movember moustaches push €1.75m into cancer research (Irish Times)
• Research to track progress of prostate patients (Irish Independent)
• Prostate cancer probe is world first (The Herald)

Note: Links to external websites are included on this page. The Irish Cancer Society is not responsible for the contents of external websites.